Watson Labs Teva Company Profile
✉ Email this page to a colleague
What is the competitive landscape for WATSON LABS TEVA, and what generic and branded alternatives to WATSON LABS TEVA drugs are available?
WATSON LABS TEVA has fifty approved drugs.
There are two tentative approvals on WATSON LABS TEVA drugs.
Drugs and US Patents for Watson Labs Teva
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs Teva | TRIENTINE HYDROCHLORIDE | trientine hydrochloride | CAPSULE;ORAL | 207567-001 | Feb 7, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Watson Labs Teva | BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE | bisoprolol fumarate; hydrochlorothiazide | TABLET;ORAL | 075469-003 | Sep 25, 2000 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Watson Labs Teva | ESTROPIPATE | estropipate | TABLET;ORAL | 081215-001 | Sep 23, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for WATSON LABS TEVA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
Similar Applicant Names
Here is a list of applicants with similar names.